Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study
暂无分享,去创建一个
M. Herkenham | M. D. Little | K. Bankiewicz | S. P. Markey | J. Johannessen | S.-C. Yang | Miles Herkenham
[1] D. Scherman,et al. Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin , 1989, Neuroscience.
[2] H. Narabayashi,et al. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology , 1988, Brain Research.
[3] S. Markey,et al. Recommended safe practices for using the neurotoxin MPTP in animal experiments. , 1988, Laboratory animal science.
[4] S. Markey,et al. Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. , 1988, Chemical research in toxicology.
[5] A. Crane,et al. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates , 1988, Brain Research.
[6] A. Cesura,et al. Uptake, Release, and Subcellular Localization of l‐Methyl‐4‐Phenylpyridinium in Blood Platelets , 1987, Journal of neurochemistry.
[7] M. Horne,et al. MPTP, impairment of motor performance and amine accumulation in Macaca fasicularis , 1987, Brain Research Bulletin.
[8] E. Sundström,et al. Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice. , 1986, European journal of pharmacology.
[9] D. Jacobowitz,et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.
[10] D. Price,et al. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey , 1986, Neuroscience.
[11] S. Snyder,et al. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.
[12] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[13] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[14] P. Goldman-Rakic,et al. Region‐specific distribution of catecholamine afferents in primate cerebral cortex: A fluorescence histochemical analysis , 1984, The Journal of comparative neurology.
[15] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[16] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[17] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[18] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[19] L. Swanson,et al. The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat , 1982, Brain Research Bulletin.
[20] M. Ishikawa,et al. Histochemical mapping of catecholaminergic neurons and their ascending fiber pathways in the rhesus monkey brain , 1982, Brain Research Bulletin.
[21] D. Felten,et al. Monoamine distribution in primate brain. V. Monoaminergic nuclei: Anatomy, pathways, and local organization , 1982, Brain Research Bulletin.
[22] C. Saper,et al. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. , 1982, Brain : a journal of neurology.
[23] P. Goldman-Rakic,et al. Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP , 1982, The Journal of comparative neurology.
[24] M Mishkin,et al. Organization of the amygdalopetal projections from modality‐specific cortical association areas in the monkey , 1980, The Journal of comparative neurology.
[25] L. Sokoloff,et al. Computerized densitometry and color coding of [14C] deoxyglucose autoradiographs , 1980, Annals of neurology.
[26] W. Nauta,et al. Efferent connections of the substantia nigra and ventral tegmental area in the rat , 1979, Brain Research.
[27] L. Wolfson,et al. Juvenile parkinsonism: A patient with possible primary striatal dysfunction , 1978, Annals of neurology.
[28] P. Maclean,et al. A brainstem atlas of catecholaminergic neurons and serotonergic perikarya in a pygmy primate (Cebuella pygmaea) , 1978, The Journal of comparative neurology.
[29] T. Sourkes,et al. INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM. , 1965, Brain : a journal of neurology.
[30] M. Monnier,et al. A Stereotaxic Atlas of the Monkey Brain , 1962 .
[31] D. Jacobowitz,et al. N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. , 1984, Psychopharmacology bulletin.
[32] K. Fuxe,et al. FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT. , 1965, The American journal of anatomy.